ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FAB Fusion Antibodies Plc

3.20
-0.15 (-4.48%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Fusion Antibodies Plc FAB London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.15 -4.48% 3.20 10:17:37
Open Price Low Price High Price Close Price Previous Close
3.35 3.20 3.35 3.20 3.35
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Fusion Antibodies FAB Dividends History

No dividends issued between 22 Jun 2014 and 22 Jun 2024

Top Dividend Posts

Top Posts
Posted at 23/5/2024 08:20 by citys2874
Yes great news out today for FAB and IXI should both rally
Posted at 30/4/2024 12:59 by jaknife
Yet another poor trading update for this POS company:



It's not true what the adverts say that "past performance is not a guide to future performance", it is 100% the case that "once a dog, always a dog"!

JakNife
Posted at 02/4/2024 14:56 by beatme1
Yep fab considering delisting needs shareholder vote to agree
Posted at 02/4/2024 08:38 by beatme1
Hearing fab want to delist following other pharma stocks
Posted at 27/2/2024 10:31 by troutisout
"Fusion Antibodies (FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announced it has received a first purchase order under the master services agreement (MSA) with a leading diagnostics company details of which were announced on 14 February 2024. FAB said reaching this agreement with a world class diagnostics provider positively reinforces the value to the wider commercial world of Fusion Antibodies’ technologies and capabilities. In this case it is the generation of antibodies in diagnostics products.

Comment: It could be argued that fundamentally FAB is now on track as a recovery situation, with the purchase order and recent funding. Only a rise in the share price is missing."
Posted at 14/2/2024 10:14 by jaknife
^^ what clocktower said

I really don't understand why the longs couldn't see this coming. Anyone should be able to do the really basic maths to see that FAB is a sub-scale business that needs a dramatic transformation before it will become profitable. The consequence of it NOT being profitable is that it's loss-making and hence cash-burning and dependent on regular fund raises.

They raised £1.56m at 5p in May last year and now have raised £1.38m at 4p. Who will be surprised if they raise another £1.4m a year from now at 3p? You shouldn't be!

JakNife
Posted at 23/1/2024 16:30 by jaknife
I have no particular interest in FAB anymore, it's too small a company. But I would be interested to see any calculations that anyone has done of (a) what FAB's current monthly cash burn is, and (b) therefore what FAB's current cash position is.

Do people routinely do these sorts of calculations before investing?

JakNife
Posted at 23/12/2023 12:17 by porky9
Anyone here with solid research can you tell me in layman's terms in relation to the NCI collaboration what they mean by the statement:-

“The validation will be run at NCI's laboratories by their staff and antibodies identified pursuant to the Agreement would be retained by NCI”

So are they saying, here is our catalogue of antibodies, take your pick, NCI then spend a couple of years R&D on them against diseases they are working on finding cures for, NCI if it goes well find that antibody 1234 is effective against X and on result, it validates that FAB have a useful catalogue of antibodies but the antibody 1234 that works in this example is retained by NCI for drug dev to commercialisation?

I’m struggling to work out how FAB would financially benefit here in the event of success? If this was a license deal they would get milestone payments? In this example it looks like NCI get the catalogue for nothing but obviously have cost to R&D with it but it’s retained by NCI on success ???

Anyone care to enlighten me what I’m missing here?
Posted at 30/11/2023 14:40 by thiopia
Googling 'Mammalian Cell Display' brings up the name of a long time academic researcher on the area dating back to 2009 in terms of published research... Mitchell Ho

Guess who is the Director of the Research on Antibody Engineering (Mammalian Cell Display) at US NCI and on the Fusion Antibodies FAB RNS ? Mitchell Ho !!!

I think people are underestimating just how big a deal this could be for FAB

US Govt NCI just provides one level of validation but an important on (as well as having a multi-billion budget) but this should lead to lots of Bios and Pharmas also beating a path to FAB's door
Posted at 28/11/2023 15:25 by andymunchkin
superg118 Sep '20 - 11:01 - 217 of 3633
0 2 1
Tidy

FAB is not yet on the map as such but will be in the coming week or so.

Most booing in now won;t have adman clue about FAB they will assume big cash needed which is completely wrong. That's what I love about FAB.

Very low risk, very big upside...
----
price was 1.2op & itCrashed like crUshed candIes pmsl lYingCnTs

Your Recent History

Delayed Upgrade Clock